Cancer clinical research is my passion. The driving force for me is the hope to be able to make a contribution to the world through this work. I am highly interested and motivated in early phase biomarker-driven clinical trials that use both targeted and immunotherapies. Through cancer research my goal is to make an impact on how we treat cancer.
Poster 1291: The landscape of 2,706 RET alterations from 89,754 adult patients with cancer: Clinical implications
Poster 2988: Pan-cancer efficacy of BRAF and/or MEK inhibitors in BRAFV600-mutant multiple non-melanoma cancers: A clinico-genomic study